Cargando…

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase

Irinotecan (CPT11), a broad-spectrum cytotoxic anticancer agent, induces a series of toxic side-effects. The most conspicuous side-effect is gastrointestinal mucositis, including nausea, vomiting, and diarrhea. A growing body of evidence indicates that bacteria β-glucuronidase (GUS), an enzyme expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Bei, Gao, Ruiyang, Lv, Cheng, Yu, Zhilun, Wang, Hao, Geng, Xiaolong, Wang, Zhengtao, Dou, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593678/
https://www.ncbi.nlm.nih.gov/pubmed/34795594
http://dx.doi.org/10.3389/fphar.2021.774560
_version_ 1784599800511987712
author Yue, Bei
Gao, Ruiyang
Lv, Cheng
Yu, Zhilun
Wang, Hao
Geng, Xiaolong
Wang, Zhengtao
Dou, Wei
author_facet Yue, Bei
Gao, Ruiyang
Lv, Cheng
Yu, Zhilun
Wang, Hao
Geng, Xiaolong
Wang, Zhengtao
Dou, Wei
author_sort Yue, Bei
collection PubMed
description Irinotecan (CPT11), a broad-spectrum cytotoxic anticancer agent, induces a series of toxic side-effects. The most conspicuous side-effect is gastrointestinal mucositis, including nausea, vomiting, and diarrhea. A growing body of evidence indicates that bacteria β-glucuronidase (GUS), an enzyme expressed by intestinal microbiota, converts the inactive CPT11 metabolite SN38G to the active metabolite SN38 to ultimately induce intestinal mucositis. We sought to explore the potential efficacy and underlying mechanisms of berberine on CPT11-induced mucositis. Our study showed that berberine (50 mg/kg; i. g.) mitigated the CPT11-induced loss of mucosal architecture, ulceration, and neutrophil infiltration. Meanwhile, berberine improved mucosal barrier function by increasing the number of globlet cells, protecting trans-endothelial electrical resistance (TEER), reducing permeability and increasing tight junction proteins expression. LC-MS analysis showed that berberine decreased the content of SN38 in feces, which correlated with decreases in both GUS activity and GUS-producing bacteria. Further molecular docking and Lineweaver-Burk plots analyses suggested that berberine functions as a potential non-competitive inhibitor against GUS enzyme. Of note, berberine maintained the anti-tumor efficacy of CPT11 in a tumor xenograft model while abrogating the intestinal toxicity of CPT11. Overall, we identified for the first time the remission effects of berberine on intestinal mucositis induced by CPT11 without impairing the anti-colorectal cancer efficacy of CPT11 partially via inhibiting bacterial GUS enzyme.
format Online
Article
Text
id pubmed-8593678
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85936782021-11-17 Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase Yue, Bei Gao, Ruiyang Lv, Cheng Yu, Zhilun Wang, Hao Geng, Xiaolong Wang, Zhengtao Dou, Wei Front Pharmacol Pharmacology Irinotecan (CPT11), a broad-spectrum cytotoxic anticancer agent, induces a series of toxic side-effects. The most conspicuous side-effect is gastrointestinal mucositis, including nausea, vomiting, and diarrhea. A growing body of evidence indicates that bacteria β-glucuronidase (GUS), an enzyme expressed by intestinal microbiota, converts the inactive CPT11 metabolite SN38G to the active metabolite SN38 to ultimately induce intestinal mucositis. We sought to explore the potential efficacy and underlying mechanisms of berberine on CPT11-induced mucositis. Our study showed that berberine (50 mg/kg; i. g.) mitigated the CPT11-induced loss of mucosal architecture, ulceration, and neutrophil infiltration. Meanwhile, berberine improved mucosal barrier function by increasing the number of globlet cells, protecting trans-endothelial electrical resistance (TEER), reducing permeability and increasing tight junction proteins expression. LC-MS analysis showed that berberine decreased the content of SN38 in feces, which correlated with decreases in both GUS activity and GUS-producing bacteria. Further molecular docking and Lineweaver-Burk plots analyses suggested that berberine functions as a potential non-competitive inhibitor against GUS enzyme. Of note, berberine maintained the anti-tumor efficacy of CPT11 in a tumor xenograft model while abrogating the intestinal toxicity of CPT11. Overall, we identified for the first time the remission effects of berberine on intestinal mucositis induced by CPT11 without impairing the anti-colorectal cancer efficacy of CPT11 partially via inhibiting bacterial GUS enzyme. Frontiers Media S.A. 2021-11-02 /pmc/articles/PMC8593678/ /pubmed/34795594 http://dx.doi.org/10.3389/fphar.2021.774560 Text en Copyright © 2021 Yue, Gao, Lv, Yu, Wang, Geng, Wang and Dou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yue, Bei
Gao, Ruiyang
Lv, Cheng
Yu, Zhilun
Wang, Hao
Geng, Xiaolong
Wang, Zhengtao
Dou, Wei
Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
title Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
title_full Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
title_fullStr Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
title_full_unstemmed Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
title_short Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
title_sort berberine improves irinotecan-induced intestinal mucositis without impairing the anti-colorectal cancer efficacy of irinotecan by inhibiting bacterial β-glucuronidase
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593678/
https://www.ncbi.nlm.nih.gov/pubmed/34795594
http://dx.doi.org/10.3389/fphar.2021.774560
work_keys_str_mv AT yuebei berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase
AT gaoruiyang berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase
AT lvcheng berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase
AT yuzhilun berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase
AT wanghao berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase
AT gengxiaolong berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase
AT wangzhengtao berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase
AT douwei berberineimprovesirinotecaninducedintestinalmucositiswithoutimpairingtheanticolorectalcancerefficacyofirinotecanbyinhibitingbacterialbglucuronidase